| Bistability analyses of a caspase activation model for receptor-induced apoptosis T Eissing, H Conzelmann, ED Gilles, F Allgower, E Bullinger, P Scheurich Journal of Biological Chemistry 279 (35), 36892-36897, 2004 | 389 | 2004 |
| Applied concepts in PBPK modeling: how to build a PBPK/PD model L Kuepfer, C Niederalt, T Wendl, JF Schlender, S Willmann, J Lippert, ... CPT: pharmacometrics & systems pharmacology 5 (10), 516-531, 2016 | 357 | 2016 |
| A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks T Eissing, L Kuepfer, C Becker, M Block, K Coboeken, T Gaub, L Goerlitz, ... Frontiers in physiology 2, 4, 2011 | 274 | 2011 |
| PBPK models for CYP3A4 and P‐gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin N Hanke, S Frechen, D Moj, H Britz, T Eissing, T Wendl, T Lehr CPT: pharmacometrics & systems pharmacology 7 (10), 647-659, 2018 | 146 | 2018 |
| Development of a whole-body physiologically based pharmacokinetic approach to assess the pharmacokinetics of drugs in elderly individuals JF Schlender, M Meyer, K Thelen, M Krauss, S Willmann, T Eissing, ... Clinical pharmacokinetics 55, 1573-1589, 2016 | 124 | 2016 |
| Gestation-specific changes in the anatomy and physiology of healthy pregnant women: an extended repository of model parameters for physiologically based pharmacokinetic … A Dallmann, I Ince, M Meyer, S Willmann, T Eissing, G Hempel Clinical pharmacokinetics 56, 1303-1330, 2017 | 115 | 2017 |
| Robustness properties of apoptosis models with respect to parameter variations and intrinsic noise T Eißing, F Allgöwer, E Bullinger IEE Proceedings-Systems Biology 152 (4), 221-228, 2005 | 107 | 2005 |
| Bistable biological systems: A characterization through local compact input-to-state stability M Chaves, T Eissing, F Allgower IEEE Transactions on Automatic Control 53 (Special Issue), 87-100, 2008 | 103 | 2008 |
| A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim C Niederalt, L Kuepfer, J Solodenko, T Eissing, HU Siegmund, M Block, ... Journal of pharmacokinetics and pharmacodynamics 45, 235-257, 2018 | 92 | 2018 |
| A generic integrated physiologically based whole‐body model of the glucose‐insulin‐glucagon regulatory system S Schaller, S Willmann, J Lippert, L Schaupp, TR Pieber, A Schuppert, ... CPT: pharmacometrics & systems pharmacology 2 (8), 1-10, 2013 | 88 | 2013 |
| Physiologically based pharmacokinetic modeling of renally cleared drugs in pregnant women A Dallmann, I Ince, J Solodenko, M Meyer, S Willmann, T Eissing, ... Clinical pharmacokinetics 56, 1525-1541, 2017 | 86 | 2017 |
| Dynamics on and of complex networks N Ganguly, A Deutsch, A Mukherjee Applications to Biology, Computer Science, and the Social Sciences, 2009 | 81 | 2009 |
| First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development A Strougo, T Eissing, A Yassen, S Willmann, M Danhof, J Freijer Journal of pharmacokinetics and pharmacodynamics 39, 195-203, 2012 | 80 | 2012 |
| A physiologically based pharmacokinetic model for pregnant women to predict the pharmacokinetics of drugs metabolized via several enzymatic pathways A Dallmann, I Ince, K Coboeken, T Eissing, G Hempel Clinical pharmacokinetics 57, 749-768, 2018 | 79 | 2018 |
| Physiologically based pharmacokinetic modeling in pregnancy: a systematic review of published models A Dallmann, M Pfister, J van den Anker, T Eissing Clinical Pharmacology & Therapeutics 104 (6), 1110-1124, 2018 | 71 | 2018 |
| Applied concepts in PBPK modeling: how to extend an open systems pharmacology model to the special population of pregnant women A Dallmann, J Solodenko, I Ince, T Eissing CPT: pharmacometrics & systems pharmacology 7 (7), 419-431, 2018 | 58 | 2018 |
| Response to bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores T Eissing, S Waldherr, F Allgöwer, P Scheurich, E Bullinger Biophysical journal 92 (9), 3332-3334, 2007 | 55 | 2007 |
| NT‐proBNP qualifies as a surrogate for clinical end points in heart failure W Schmitt, H Rühs, R Burghaus, C Diedrich, S Duwal, T Eissing, ... Clinical Pharmacology & Therapeutics 110 (2), 498-507, 2021 | 47 | 2021 |
| Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 … T Eissing, J Lippert, S Willmann Molecular diagnosis & therapy 16, 43-53, 2012 | 47 | 2012 |
| Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug–Drug–Gene Interactions: A Modeling Network … D Türk, N Hanke, S Wolf, S Frechen, T Eissing, T Wendl, M Schwab, ... Clinical Pharmacokinetics 58, 1595-1607, 2019 | 45 | 2019 |
Stefan WillmannBayer AGVerified email at drwillmann.de
